Optical metabolic imaging measures early drug response in an allograft murine breast cancer model (Conference Presentation)

Joe T. Sharick; Rebecca S. Cook; Melissa C. Skala

doi:10.1117/12.2252803

19 April 2017 Optical metabolic imaging measures early drug response in an allograft murine breast cancer model (Conference Presentation)

Joe T. Sharick, Rebecca S. Cook, Melissa C. Skala

Author Affiliations +

Proceedings Volume 10043, Diagnosis and Treatment of Diseases in the Breast and Reproductive System; 1004308 (2017) https://doi.org/10.1117/12.2252803
Event: SPIE BiOS, 2017, San Francisco, California, United States

Abstract

Previous work has shown that cellular-level Optical Metabolic Imaging (OMI) of organoids derived from human breast cancer cell-line xenografts accurately and rapidly predicts in vivo response to therapy. To validate OMI as a predictive measure of treatment response in an immune-competent model, we used the polyomavirus middle-T (PyVmT) transgenic mouse breast cancer model. The PyVmT model includes intra-tumoral heterogeneity and a complex tumor microenvironment that can influence treatment responses. Three-dimensional organoids generated from primary PyVmT tumor tissue were treated with a chemotherapy (paclitaxel) and a PI3K inhibitor (XL147), each alone or in combination. Cellular subpopulations of response were measured using the OMI Index, a composite endpoint of metabolic response comprised of the optical redox ratio (ratio of the fluorescence intensities of metabolic co-enzymes NAD(P)H to FAD) as well as the fluorescence lifetimes of NAD(P)H and FAD. Combination treatment significantly decreased the OMI Index of PyVmT tumor organoids (p<0.0001) and in vivo tumors (p<0.0001) versus controls. Subpopulation analyses revealed a homogeneous response to combined therapy in both cultured organoids and in vivo tumors, while single agent treatment with XL147 alone or paclitaxel alone elicited heterogeneous responses in organoids. Tumor volume decreased with combination treatment through treatment day 30. These results indicate that OMI of organoids generated from PyVmT tumors can accurately reflect drug response in heterogeneous allografts with both innate and adaptive immunity. Thus, this method is promising for use in humans to predict long-term treatment responses accurately and rapidly, and could aid in clinical treatment planning.

Conference Presentation

Citation Download Citation

Joe T. Sharick, Rebecca S. Cook, and Melissa C. Skala "Optical metabolic imaging measures early drug response in an allograft murine breast cancer model (Conference Presentation)", Proc. SPIE 10043, Diagnosis and Treatment of Diseases in the Breast and Reproductive System, 1004308 (19 April 2017); https://doi.org/10.1117/12.2252803

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available